SV2 PET Imaging With [11C]APP311

Description

The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

Conditions

Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy

Talk to us

Study Overview

On this page

Study Details

Study overview

The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311

SV2 PET Imaging With [11C]APP311

Condition
Schizophrenia and Other Psychotic Disorders
Intervention / Treatment

-

Contacts and Locations

New Haven

Conneticut Mental Health Center, New Haven, Connecticut, United States, 06519

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Willing and able to give voluntary written informed consent
  • * Male and Female subjects, age 18 to 65 years, inclusive
  • * MRI metal exclusions and claustrophobia.
  • * Education completed is less than 12 years

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Yale University,

Study Record Dates

2025-12